文献速递产科

引产方法:有效性与安全性

Methods for the induction of labor: efficacy and safety.
PubMed 文献 · Am J Obstet Gynecol · 2023-07-13

本综述评估了药物、机械及补充医学引产方法的有效性与安全性,包括米索前列醇、前列腺素E2、缩宫素、米非司酮等药物,以及球囊导管、剥膜、人工破膜等机械方法和补充医学方法。米索前列醇阴道给药50 μg在24小时内实现阴道分娩的概率最高,前列腺素E2在降低剖宫产率方面效果相似,缩宫素效果取决于产次和宫颈状态,单球囊与双球囊效果相似,米索前列醇联合宫颈内导管似乎是兼顾分娩时间与安全性的最佳方案。

要点

  • 米索前列醇(PGE1)用于宫颈成熟和引产的安全性和有效性得到2项大型网状Meta分析支持。
  • 阴道给予米索前列醇50 μg在24小时内实现阴道分娩的概率最高。
  • 前列腺素E2在降低剖宫产率方面效果相似, regardless of dosing, route, and schedule。

核心结论

  • 大量已发表报告(包括2项大型网状Meta分析)支持米索前列醇(PGE1)用于宫颈成熟和引产的安全性和有效性。
  • 阴道给予米索前列醇50 μg在24小时内实现阴道分娩的概率最高。
  • 前列腺素E2在降低剖宫产率方面似乎具有相似的有效性, regardless of dosing, route, and schedule。
  • 缩宫素比期待管理更有效地引产,与人工破膜联合可增强效果,但阴道或宫颈内给予前列腺素比缩宫素更有效。
  • 米索前列醇联合宫颈内导管似乎是兼顾分娩时间与安全性的最佳方案。

研究设计与样本

  • 本综述评估了药物、机械及补充医学引产方法的有效性与安全性。

主要发现

  • 阴道给予米索前列醇50 μg在24小时内实现阴道分娩的概率最高。
  • 前列腺素E2在降低剖宫产率方面似乎具有相似的有效性, regardless of dosing, route, and schedule。
  • 缩宫素效果高度依赖产次和宫颈状态;缩宫素比期待管理更有效,与人工破膜联合可增强效果;阴道或宫颈内给予前列腺素比缩宫素更有效。
  • 单次口服米非司酮200 mg片剂似乎是宫颈成熟的最低有效剂量。
  • 松弛素用于该适应症的益处有限;宫颈内注射透明质酸酶可促宫颈成熟但应用受限;一氧化氮供体副作用发生率较高限制其使用;合成吸水性宫颈扩张器对引产前宫颈成熟有效;单球囊与双球囊效果相似;米索前列醇联合宫颈内导管似乎是兼顾分娩时间与安全性的最佳方案。

关键数值与推荐

  • 阴道给予米索前列醇50 μg在24小时内实现阴道分娩的概率最高。
  • 单次口服米非司酮200 mg片剂似乎是宫颈成熟的最低有效剂量。
  • 前列腺素E2在降低剖宫产率方面似乎具有相似的有效性, regardless of dosing, route, and schedule。

临床怎么用

  • 米索前列醇(PGE1)用于宫颈成熟和引产的安全性和有效性得到支持。
  • 缩宫素比期待管理更有效地引产,与人工破膜联合可增强效果。
  • 米索前列醇联合宫颈内导管似乎是兼顾分娩时间与安全性的最佳方案。
  • 补充医学方法因缺乏有效性和安全性数据,在医院环境中很少使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review assessed the efficacy and safety of pharmacologic agents (prostaglandins, oxytocin, mifepristone, hyaluronidase, and nitric oxide donors) and mechanical methods (single- and double-balloon catheters, laminaria, membrane stripping, and amniotomy) and those generally considered under the rubric of complementary medicine (castor oil, nipple stimulation, sexual intercourse, herbal medicine, and acupuncture). A substantial body of published reports, including 2 large network meta-analyses, support the safety and efficacy of misoprostol (PGE1) when used for cervical ripening and labor induction. Misoprostol administered vaginally at doses of 50 μg has the highest probability of achieving vaginal delivery within 24 hours. Regardless of dosing, route, and schedule of administration, when used for cervical ripening and labor induction, prostaglandin E2 seems to have similar efficacy in decreasing cesarean delivery rates. Globally, although oxytocin represents the most widely used pharmacologic agent for labor induction, its effectiveness is highly dependent on parity and cervical status. Oxytocin is more effective than expectant management in inducing labor, and the efficacy of oxytocin is enhanced when combined with amniotomy. However, prostaglandins administered vaginally or intracervically are more effective in inducing labor than oxytocin. A single 200-mg oral tablet of mifepristone seems to represent the lowest effective dose for cervical ripening. The bulk of the literature assessing relaxin suggests this agent has limited benefit when used for this indication. Although intracervical injection of hyaluronidase may cause cervical ripening, the need for intracervical administration has limited the use of this agent. Concerning the vaginal administration of nitric oxide donors, including isosorbide mononitrate, isosorbide, nitroglycerin, and sodium nitroprusside, the higher incidence of side effects with these agents has limited their use. A synthetic hygroscopic cervical dilator has been found to be effective for preinduction cervical ripening. Although a pharmacologic agent may be administered after the use of the synthetic hygroscopic dilator, in an attempt to reduce the interval to vaginal delivery, concomitant use of mechanical and pharmacologic methods is being explored. Combining the use of a single-balloon catheter with dinoprostone, misoprostol, or oxytocin enhances the efficacy of these pharmacologic agents in cervical ripening and labor induction. The efficacy of single- and double-balloon catheters in cervical ripening and labor induction seems similar. To date, the combination of misoprostol with an intracervical catheter seems to be the best approach when balancing delivery times with safety. Although complementary methods are occasionally used by patients, given the lack of data documenting their efficacy and safety, these methods are rarely used in hospital settings.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sanchez-Ramos L, Levine LD, Sciscione AC, et al. Methods for the induction of labor: efficacy and safety. Am J Obstet Gynecol. 2023. PMID: 38462252. doi:10.1016/j.ajog.2023.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。